Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537590 | 0.82 | ATM (0.56) | ATMRAB9AABCC1NPC1ALDH1A1 | |
| SCHEMBL4030960 | 0.78 | FAAH (0.52) | NPSR1ALDH1A1LMNAHTTKDM4E | |
| SCHEMBL4029460 | 0.77 | NPSR1 (0.61) | NPSR1ALDH1A1HTTKDM4ENTRK1 | |
| SCHEMBL4030961 | 0.74 | LMNA (0.47) | NPSR1RAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL5527223 | 0.73 | MEN1 (0.61) | NPSR1ALDH1A1HTTKDM4ENTRK1 | |
| SCHEMBL26605784 | 0.73 | ATM (0.64) | ATMNPSR1RAB9AABCC1NPC1 | |
| SCHEMBL11599130 | 0.73 | ATM (1.00) | ATMRAB9AABCC1NPC1ALDH1A1 | |
| SCHEMBL17790727 | 0.72 | MAPT (0.60) | NPSR1ALDH1A1HTTKDM4ENTRK1 | |
| SCHEMBL22256920 | 0.70 | ATM (0.44) | ATMRAB9AABCC1NPC1KDM4E | |
| SCHEMBL22257222 | 0.70 | TRPV1 (0.45) | ATMRAB9AABCC1NPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | ATM 2072/4885NPSR1 62/4885RAB9A 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.